Impaired cardiac and peripheral hemodynamic responses to inhaled β₂-agonist in cystic fibrosis

Respiratory Research
Erik H Van ItersonEric M Snyder

Abstract

Pulmonary system dysfunction is a hallmark of cystic fibrosis (CF) disease. In addition to impaired cystic fibrosis transmembrane conductance regulator protein, dysfunctional β2-adrenergic receptors (β2AR) contribute to low airway function in CF. Recent observations suggest CF may also be associated with impaired cardiac function that is demonstrated by attenuated cardiac output (Q), stroke volume (SV), and cardiac power (CP) at both rest and during exercise. However, β2AR regulation of cardiac and peripheral vascular tissue, in-vivo, is unknown in CF. We have previously demonstrated that the administration of an inhaled β-agonist increases SV and Q while also decreasing SVR in healthy individuals. Therefore, we aimed to assess cardiac and peripheral hemodynamic responses to the selective β2AR agonist albuterol in individuals with CF. 18 CF and 30 control (CTL) subjects participated (ages 22 ± 2 versus 27 ± 2 and BSA = 1.7 ± 0.1 versus 1.8 ± 0.0 m(2), both p < 0.05). We assessed the following at baseline and at 30- and 60-minutes following nebulized albuterol (2.5mg diluted in 3.0mL of normal saline) inhalation: 12-lead ECG for HR, manual sphygmomanometry for systolic and diastolic blood pressure (SBP and DBP, respectively), ac...Continue Reading

References

Apr 30, 1992·The New England Journal of Medicine·E KeremH Levison
Jul 1, 1992·Pflügers Archiv : European journal of physiology·M BoutjdirN el-Sherif
Nov 1, 1992·American Journal of Respiratory Cell and Molecular Biology·E PuchelleW Dalemans
Dec 17, 1992·The New England Journal of Medicine·P A NixonC F Doershuk
Aug 1, 1990·Circulation·M R Bristow
Jun 26, 1980·The New England Journal of Medicine·P B DavisM Kaliner
Feb 1, 1984·The American Review of Respiratory Disease·J E HansenK Wasserman
Feb 24, 2001·American Journal of Epidemiology·T G LiouB C Marshall
Jul 27, 2002·Pharmacogenetics·Rainer BüscherFelix Ratjen
Dec 28, 2002·Proceedings of the National Academy of Sciences of the United States of America·Anjaparavanda P NarenJohn P Clancy
Feb 18, 2005·Acta Pharmacologica Sinica·Da-yue DuanJoseph R Hume
Apr 5, 2005·Pediatric Pulmonology·Meeghan A HartMitchell L Drumm
Jul 19, 2005·Journal of Applied Physiology·Eric M SnyderKenneth C Beck
Aug 2, 2005·The European Respiratory Journal·M R MillerUNKNOWN ATS/ERS Task Force
Jul 14, 2006·Clinical Physiology and Functional Imaging·Paul D BromleyDavid A Brodie
May 1, 2007·Pediatric Pulmonology·J M CourtneyJ S Elborn
May 16, 2007·Pharmacogenetics and Genomics·Wendy K SteagallJoel Moss
Oct 20, 2007·Biological Reviews of the Cambridge Philosophical Society·Shinichi Nakagawa, Innes C Cuthill
Jul 22, 2008·The Journal of Pediatrics·Philip M FarrellUNKNOWN Cystic Fibrosis Foundation
Sep 5, 2009·American Journal of Respiratory and Critical Care Medicine·Patrick A FlumeUNKNOWN Clinical Practice Guidelines for Pulmonary Therapies Committee
Nov 10, 2009·American Journal of Physiology. Heart and Circulatory Physiology·Masashi J IchinoseDonal S O'Leary
Nov 6, 2010·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Courtney M WheatleyEric M Snyder
Jan 12, 2011·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·James H HullRachel Garrod
Mar 9, 2011·Exercise and Sport Sciences Reviews·Courtney M WheatleyEric M Snyder
Mar 3, 2012·European Journal of Pharmacology·Zachary M SellersPhilip M Best
Jul 11, 2012·Medicine and Science in Sports and Exercise·Sarah E BakerEric M Snyder
Dec 28, 2012·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Zachary M SellersPhilip M Best
Feb 22, 2013·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Marty D SprangerDonal S O'Leary

❮ Previous
Next ❯

Citations

Sep 1, 2016·Respiratory Medicine·Fabien LabombardaPaul Milliez
Aug 28, 2018·Clinical Medicine Insights. Circulatory, Respiratory and Pulmonary Medicine·Michael PallinJohn W Wilson
Apr 17, 2016·American Journal of Physiology. Heart and Circulatory Physiology·Paula Rodriguez-MiguelezRyan A Harris
Apr 9, 2019·Clinical Medicine Insights. Circulatory, Respiratory and Pulmonary Medicine·Alexander L BischEric M Snyder
Aug 8, 2018·Clinical Medicine Insights. Circulatory, Respiratory and Pulmonary Medicine·Erik H Van ItersonEric M Snyder
Dec 7, 2020·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Ya-Ping ZhangDayue Darrel Duan

❮ Previous
Next ❯

Methods Mentioned

BETA
genotyping
blood draw

Software Mentioned

SAS

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CFTR Mutant Structural Therapy

Over 1700 different mutations in the CFTR genes have been shown to cause cystic fibrosis. Here is the latest research on structural therapy for CFTR mutants.

Cardiovascular Homeostasis

Cardiovascular regulation and homeostasis is important in maintaining health and dysfunction may lead to cardiovascular diseases. Nitric oxide and vascular endothelium are one of many molecules involved in the homeostatic mechanism. Here is the latest research on cardiovascular homeostasis.

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.